Merck agrees to buy Bio-Techne for USD 73 per share in cash, valuing deal at USD 11.3 billion

Bio-Techne Corporation
Merck & Co., Inc.

Bio-Techne Corporation

TECH

0.00

Merck & Co., Inc.

MRK

0.00
  • Merck agreed to acquire Bio-Techne for USD 73 per share in cash, valuing the deal at about USD 11.3 billion (EUR 9.9 billion).
  • Bio-Techne is a Minneapolis-based supplier of life science tools, analytical technologies, and consumables.
  • The offer implies a 36% premium to the one-month volume-weighted average share price.
  • Financing will combine existing cash with new loans, with Merck aiming to maintain a strong investment-grade rating.
  • Closing is subject to regulatory clearances and approval by Bio-Techne shareholders.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Merck KGaA published the original content used to generate this news brief via EQS News (Ref. ID: adhoc_2353908_de) on June 25, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.